Access comprehensive financial analyses and make smarter investments - get the Manual of Investments on Amazon!

BAP

Analyzing Credicorp's Stock Performance

Shares of Credicorp have moved -0.0% today, and are now trading at a price of $261.89. In contrast, the S&P 500 index saw a 0.0% change. Today's trading volume is 26,535 compared to the stock's average volume of 352,052.

Credicorp Ltd. provides various financial, insurance, and health services and products in Peru and internationally. Based in Lima, Peru the company has 38,641 full time employees and a market cap of $20,785,246,208. Credicorp currently offers its equity investors a dividend that yields 15.3% per year.

The company is now trading -0.27% away from its average analyst target price of $262.61 per share. The 12 analysts following the stock have set target prices ranging from $219.0 to $318.264, and on average give Credicorp a rating of buy.

Over the last 52 weeks, BAP stock has risen 46.0%, which amounts to a 29.7% difference compared to the S&P 500. The stock's 52 week high is $280.88 whereas its 52 week low is $165.51 per share. With its net margins declining an average -1.2% over the last 6 years, Credicorp may not have a strong enough profitability trend to support its stock price.

Date Reported Total Revenue ($ k) Net Profit ($ k) Net Margins (%) YoY Growth (%)
2024 27,472,000 5,623,252 20 5.26
2023 25,665,000 4,959,878 19 -17.39
2022 20,919,000 4,760,110 23 21.05
2021 19,452,000 3,671,829 19 850.0
2020 18,415,000 334,138 2 -90.91
2019 19,674,000 4,352,331 22
The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS